|
|
|
| 【主 题】 ： |
Cariprazine |
| 【联系人名】 ： |
Linna Green |
| 【电子邮件】 ： |
account@bocsci.com |
| 【联系电话】 ： |
15166698109 |
| 【发布日期】 ： |
2016-9-6 |
| 【详细说明】 ： |
"Cariprazine is an antipsychotic drug developed by
Gedeon Richter.It acts as a D2 and D3 receptor
partial agonist, with high selectivity towards the
D3 receptor.Positive Phase III study results were
published for schizophrenia and mania in early 2012,
and for bipolar disorder I depression from a Phase
II trial in 2015.Action on the dopaminergic systems
makes it also potentially useful as an add-on
therapy in major depressive disorder.
IC50 Value= 0.5 and 0.09 nM (for D2 and D3 receptor
respectively), Ki=2.6 and 180 nM （for D2 and D3
receptor respectively)
In vivo: Doses ≥ 1.5 mg/d yielded 69 - 75% D2/D3
receptor occupancy as measured in positron emission
tomography scans. Mean half-life for cariprazine was
2 - 5 d over a dose range of 1.5 - 12.5 mg"
http://www.bocsci.com/cariprazine-cas-839712-12-8-
item-468170.html
|
|
|
|
|
English
